Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts

BACKGROUND: Prostate cancer is a significant health problem among American men. Treatment strategies for androgen-independent cancer are currently not available. Tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is a death receptor ligand that can induce apoptosis in a variety of...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Zawahry, Ahmed, McKillop, John, Voelkel-Johnson, Christina
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC546011/
https://www.ncbi.nlm.nih.gov/pubmed/15638938
http://dx.doi.org/10.1186/1471-2407-5-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC546011/
https://www.ncbi.nlm.nih.gov/pubmed/15638938
http://dx.doi.org/10.1186/1471-2407-5-2

Ejemplares similares